Swiss medical company Medacta officially initiated the commercial use of 3DMetal Femoral Cones for revision knee arthroplasty after successfully receiving clearance from the U.S. Food and Drug Administration (FDA) and CE marking.
3DMetal is an advanced biomaterial, manufactured utilizing EBM 3D printing technology. Built upon the clinical success of 3DMetalTM Tibial Cones, the Femoral Cones can be used for structural support in areas of bone deficiencies that may compromise revision implant fixation and are indicated for use with Medacta’s GMK Revision and GMK Hinge Knee systems.
Dr. David W. Manning, Vice-Chair of the Department of Orthopaedic Surgery at the Feinberg School of Medicine at Northwestern University in Chicago, IL, designer of the 3DMetalTM Femoral Cones said: “The 3DMetal Femoral Cones from Medacta are extremely versatile, utilize the clinically proven 3DMetal technology and are very user friendly for surgeons looking to restore metaphyseal and metadiaphyseal structures from which to build a revision TKA construct. The addition of these cones to the Medacta revision portfolio allows me to efficiently and reliably tackle the most difficult femoral revision scenarios.”
The 3DMetalTM Femoral Cones are characterized by a triple-layer structure, patented by Medacta, with a middle full-density layer to avoid cement protrusion through the outer layer pores and increases the mechanical properties of the implant. The innovative interconnecting pore structure of these implants, similar to that of native cancellous bone, enables direct mechanical and functional connection with the bone.
This new implant further expands Medacta’s offering for knee arthroplasty, which now features a broader range of options for revision surgery and complex cases.